Gynofem Healthcare
1 MAbout Gynofem Healthcare
A Comprehensive Overview of Price & Journey
Understanding Gynofem Healthcare Inception and Growth
Overview
Gynofem Healthcare Ltd. is a fast-growing Indian Pharmaceutical company engaged in developing and marketing a broad range of pharmaceutical products. The core strength of Gynofem lies in the development of Gynecological products. These products are specially designed to be of help to a mother willing to conceive and during her pregnancy. There are products designed by Gynofem to help those mothers unable to conceive due to clinical reasons, to conceive successfully and become a mother of a child. Gynofem products are of tremendous use to pregnant mothers, helping them to carry a healthy child. It helps mothers after their delivery and they nurse their babies to a healthy life with a complete regain of their normal health.
Gynofem Healthcare is a pharmaceutical and healthcare company specializing in women’s health and gynecological care. It primarily operates as a trading and distribution entity, supplying gynecological medicines, supplements, and wellness products to hospitals, clinics, and retail pharmacies. It belongs to the Industry of Pharmaceuticals & Healthcare. It was founded on May 27, 2016. Its Headquarters are in Indore, Madhya Pradesh, India. Its main focus is on Women's health, gynecology, fertility treatments, and wellness supplements
Products
-
Macova 2.5 Tablet
-
Rabifem-DSR Capsule
-
Save 9 Tablet
-
Z-Fem 500 Tablet
-
Derwin Gel
-
Dydrofast 10 Tablet
-
Etoder-P Tablet
-
& Many More
SHOW MORE...
Overview
Gynofem Healthcare Ltd. is a fast-growing Indian Pharmaceutical company engaged in developing and marketing a broad range of pharmaceutical products. The core strength of Gynofem lies in the development of Gynecological products. These products are specially designed to be of help to a mother willing to conceive and during her pregnancy. There are products designed by Gynofem to help those mothers unable to conceive due to clinical reasons, to conceive successfully and become a mother of a child. Gynofem products are of tremendous use to pregnant mothers, helping them to carry a healthy child. It helps mothers after their delivery and they nurse their babies to a healthy life with a complete regain of their normal health.
Gynofem Healthcare is a pharmaceutical and healthcare company specializing in women’s health and gynecological care. It primarily operates as a trading and distribution entity, supplying gynecological medicines, supplements, and wellness products to hospitals, clinics, and retail pharmacies. It belongs to the Industry of Pharmaceuticals & Healthcare. It was founded on May 27, 2016. Its Headquarters are in Indore, Madhya Pradesh, India. Its main focus is on Women's health, gynecology, fertility treatments, and wellness supplements
Products
-
Macova 2.5 Tablet
-
Rabifem-DSR Capsule
-
Save 9 Tablet
-
Z-Fem 500 Tablet
-
Derwin Gel
-
Dydrofast 10 Tablet
-
Etoder-P Tablet
-
& Many More
About Gynofem Healthcare
IPO Details, Price movement
Board of Directors
-
Nishikant Joshi, Director
-
Anurag Mendhe, Director
-
Kartikay Joshi, Director
MISSION STATEMENT
“Gynofem Healthcare Pvt. Ltd. is a company with a mission to build a stronger India in the future. Gynofem focuses on the health of a mother and a nursing mother, so that she remains healthy, gives birth to a healthy child, and hence helps build a stronger nation. Gynofem Healthcare is a company with a mission to combat malnutrition among mothers and children, fight bad health in them, and make them healthy and strong.
Gynofem Healthcare is a company with a mission to take care of the health of every mother and her child, and to keep them healthy.”
VISION STATEMENT
“Gynofem Healthcare Pvt. Ltd.’s vision is to provide innovative, high-technology products that will satisfy the needs of the patients in areas of Gynecology and Obstetrics. Gynofem Healthcare Pvt. Ltd. wishes to emerge as a technology-driven pharmaceutical company offering top-quality and cost-effective healthcare to people of this country.
Gynofem Healthcare is firmly committed to its vision. Technology, research, and Development are the highest priorities of the company. Gynofem policies are market-oriented, keeping in view the benefits of its consumers. Gynofem is committed to promoting class products.”
IPO Details
No information is provided by the company regarding the IPO plans of them. However, the Gynofem share price will likely become a key focus if the company decides to go public in the future, with market trends and investor sentiment influencing its potential valuation.
Dividend Details
No information is provided by the company regarding the Dividend.
Subsidiaries
No information is provided by the company regarding the Subsidiaries of the company.
Industry
The Indian pharmaceutical industry is booming. It jumped from $40 billion in 2021 to an expected $130 billion in 2030, with projections hitting $450 billion by 2047. Beyond just keeping up with the demand at home, the Indian pharma industry commands over 20% of the global pharma supply chain and addresses approximately 60% of the worldwide demand for vaccines.
It meets 40% of the generic demand in the US and provides a quarter of all medicines in the UK. It has undergone a remarkable transformation, evolving into a dynamic powerhouse driving healthcare advancements worldwide. Interestingly, India is the biggest contributor to UNESCO, with a share of over 50-60%. Plus, it boasts the highest number of USFDA-approved plants outside the U.S.
Fundamentals
Financials
| P&L Statement |
|---|
| Revenue |
| Other Income |
| COGS |
| Gross Profit |
| Total Expense |
| EBIDTA |
| D&A |
| EBIT |
| Interest Expense |
| PBT |
| TAX |
| PAT |
| Diluted EPS |
| Basic EPS |
| Total income |
ASSETS
| CURRENT ASSETS |
|---|
| Cash and Cash Equivalents |
| Trade Payables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| NON CURRENT ASSETS |
|---|
| Plant Property and Equipment |
| Long Term Investment |
| Other Non Current Assets |
| TOTOAL NON CURRENT ASSSETS |
| Total Assets |
|---|
| CURRENT LIABILITES |
|---|
| TRADW Payable |
| Other Current Liab |
| Total Current Liab |
| NON CURRENTLIABILITIES |
|---|
| Long Term Debt |
| Deffered Tax Liab |
| Other Non Current Liab |
LIABILITIES
| EQUITY |
|---|
| Share Capital |
| Reserves And Surplus |
| Other Equity |
| Retained Earnings |
| share Equity |
| Total Liabilities |
|---|
| CASH FLOW STAT |
|---|
| Cash Flow from operating |
| Cash Flow from financing |
| Cash Flow from investing |
| Net cash flow |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Frequently Asked Questions
The lockin period is of 6 months for pre-ipo investors i.e. they cannot sell their shares for 6 months after they get listed. However, they can definitely sell the shares in pre-ipo market before they get listed.
- With BharatInvest, you can now invest in unlisted/pre-ipo shares with as low as 25-50k depending upon the share.
- 1. You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
- 2. Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
- The value of share in unlisted space is determined in the same way as it is done in listed market. Demand and supply decide the price of any share. If the demand more than the supply, then the prices of the share increases and vice versa.
- When a new shares is introduces in the unlisted space, the value of the company is decided upon the last funding raised by company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
- A Public Unlisted Shares Is Not Listed on Stock Exchange, Where as a Listed Public Company Is Listed On Stock Exchange Such As BSE Or NSE For Trading Of Shares.
- If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unli sted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.
- If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 12.5% without indexation benefits.
- After listing of shares, the unlisted shares which you have bought through unlisted market, will be taxed at listed rates, if sold through exchange. So, taxes of listed market will be applicable. And, to calculate holding time, for determining LTCG or STCG, the purchase date of unlisted shares will be applicable.
- Absoluetly NOT! Grey market is all about speculation relation to open price, subscription rate etc. And does not include physical delivery of shares. Whereas in pre ipo market you get to invest in shares much before the ipo too and it involves physical delivery of shares. It is compeletly legal and does not include any such speculation.
- Existing stakeholders, promoters or employees who have equity shares of an unlisted company and early investors who wish to get value of their investment.
Yes, investing in unlisted shares is undoubtedly legal in India. The trading takes place in the over-the-counter market